Dr. Shah Discusses Autologous Transplant in MCL

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Not all patients with MCL in first remission should receive ASCT, says Shah. The main alternative would be rituximab (Rituxan) maintenance therapy, but there is not yet enough information on duration of treatment with this approach.

Shah says, at this point, it is up to the patient to either undergo transplant or rituximab maintenance.